1093557 - Dexcom Inc - SEC Form 4 Insider Trading Screener

Manufactured Goods - Specialty Instruments - Surgical & Medical Instruments & Apparatus - DXCM (1093557)
General
Tickers
Insider
Sh Price $
Lqdty M$
Date
Filing Date
  
Trade Date
  
Filing Delay
N Days Ago
Transaction Filing
P - Purchase
S - Sale
A - Grant
D - Sale to Iss
G - Gift
F - Tax
M - Option Ex
X - Option Ex
C - Cnv Deriv
W - Inherited
No deriv Multiple Days
Traded K$
Own Chg %
Industry
Insider Title   Officer
    COB
    CEO
    Pres
    COO
    CFO
    GC
    VP
  Director
  10% Own
  Other
Group by
Sort by
Max Results
Page
clear
Real-time CSV, Options, Alerts
100 results - Yahoo - Google - Finviz - Stockcharts - Tradingview - Stocktwits - SEC
TCcnt1d1w1m6m

X

Filing Date

Trade Date

Ticker

Insider Name

Insider Title

Trade Type 

Price

Qty

Owned

ΔOwn

Value

1d

1w

1m

6m

2018-09-14
DXCMBalo Andrew KEVP, Reg. Strategy, ClinicalS - Sale$145.17-5,00088,105-5%-$725,851
D
2018-09-12
DXCMLeach Jacob StevenSVP, Research, DevelopmentM - OptEx$5.92+15,000168,708+10%+$88,800
2018-09-11
DXCMBlackford Quentin S.EVP, CFO, PFO, PAOS - Sale$147.04-8,44087,131-9%-$1,241,028
2018-09-10
DXCMMoy JeffreySVP, OperationsS - Sale$143.53-10,33063,245-14%-$1,482,667
2018-09-10
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$143.75-5,48387,634-6%-$788,210
2018-09-10
DXCMBalo Andrew KEVP, Reg. Strategy, ClinicalS - Sale$143.75-5,58793,105-6%-$803,160
2018-09-10
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.S - Sale$143.75-5,483116,974-4%-$788,210
2018-09-10
DXCMMurphy Patrick MichaelVP, Legal Aff, Chf Compl OfcrS - Sale$143.69-2,37231,308-7%-$340,825
2018-09-10
DXCMLeach Jacob StevenSVP, Research, DevelopmentS - Sale$143.75-4,614153,708-3%-$663,286
2018-09-10
DXCMAce Heather SSVP HRS - Sale$143.75-1,83269,339-3%-$263,360
2018-09-10
DXCMAbbey DonaldEVP, Quality, Regulatory AfrsS - Sale$143.75-2,30398,639-2%-$331,068
2018-09-10
DXCMBlackford Quentin S.EVP, CFO, PFO, PAOS - Sale$143.75-7,14995,571-7%-$1,027,706
D
2018-09-10
DXCMSayer Kevin RPres, CEO, COBM - OptEx$4.58+11,161320,837+4%+$51,117
D
2018-09-10
DXCMSayer Kevin RPres, CEO, COBS - Sale+OE$143.62-25,495320,837-7%-$3,661,573
2018-08-24
DXCMAltman Steven RDirS - Sale$136.47-5,00061,304-8%-$682,359
2018-08-24
DXCMFoletta Mark GDirS - Sale$137.50-1,00021,147-5%-$137,503
D
2018-08-24
DXCMLeach Jacob StevenSVP, Research, DevelopmentM - OptEx$4.52+20,577158,302+15%+$92,941
D
2018-08-24
DXCMLeach Jacob StevenSVP, Research, DevelopmentS - Sale+OE$138.32-20,577158,302-12%-$2,846,155
2018-08-23
DXCMAce Heather SSVP HRD - Sale to issuer$141.59-3,06171,171-4%-$433,412
2018-08-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$140.03-2,58492,912-3%-$361,833
2018-08-23
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.S - Sale$139.96-3,114122,457-2%-$435,843
2018-08-14
DXCMBalo Andrew KEVP, Reg. Strategy, ClinicalS - Sale$124.25-5,00098,567-5%-$621,253
D
2018-08-13
DXCMSayer Kevin RPres, CEO, COBM - OptEx$4.58+11,161335,171+3%+$51,117
D
2018-08-13
DXCMSayer Kevin RPres, CEO, COBS - Sale+OE$123.22-11,161335,171-3%-$1,375,211
2018-08-10
DXCMMurphy Patrick MichaelVP, Legal Aff, Chf Compl OfcrS - Sale$124.19-12,50033,680-27%-$1,552,310
2018-08-06
DXCMAugustinos NicholasDirS - Sale$121.33-12,30022,164-36%-$1,492,381
2018-08-01
DXCMMoy JeffreySVP, OperationsS - Sale$94.13-5,83173,572-7%-$548,872
2018-07-25
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.S - Sale$101.91-3,114125,571-2%-$317,335
2018-07-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$102.48-2,58195,496-3%-$264,513
2018-07-16
DXCMBalo Andrew KEVP, Reg. Strategy, ClinicalS - Sale$99.56-5,000103,567-5%-$497,816
2018-07-16
DXCMGregg Terrance HExec COBS - Sale$99.56-10,000504,017-2%-$995,561
2018-07-09
DXCMSayer Kevin RPres, CEOS - Sale$99.79-14,219335,171-4%-$1,418,856
2018-06-28
DXCMMoy JeffreySVP, OperationsS - Sale$92.48-59,19379,403-43%-$5,474,297
2018-06-25
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$98.58-2,58198,077-3%-$254,431
A
2018-06-01
DXCMTopol EricDirA - Grant$0.00+3,6863,686New+$4
A
2018-06-01
DXCMSkyler Jay SDirA - Grant$0.00+3,6073,607New+$4
A
2018-06-01
DXCMKahn BarbaraDirA - Grant$0.00+3,4493,449New+$3
A
2018-06-01
DXCMCollins Richard AlexanderDirA - Grant$0.00+3,4499,304+59%+$3
A
2018-06-01
DXCMFoletta Mark GDirA - Grant$0.00+4,0524,052New+$4
A
2018-06-01
DXCMAugustinos NicholasDirA - Grant$0.00+3,44934,464+11%+$3
A
2018-06-01
DXCMAltman Steven RDirA - Grant$0.00+3,4493,449New+$3
2018-06-15
DXCMGregg Terrance HExec COBS - Sale$97.81-10,000514,017-2%-$978,096
2018-06-12
DXCMTopol EricDirS - Sale$100.10-20,00088,257-18%-$2,001,998
2018-06-08
DXCMMoy JeffreySVP, OperationsG - Gift$0.00-315138,5960%-$0
2018-06-01
DXCMAbbey DonaldEVP, Quality, Regulatory AfrsD - Sale to issuer$88.10-9,011100,942-8%-$793,869
2018-05-31
DXCMCollins Richard AlexanderDirA - Grant$0.00+3,4579,312+59%+$3
2018-05-31
DXCMFoletta Mark GDirA - Grant$0.00+4,06222,157+22%+$4
2018-05-31
DXCMSkyler Jay SDirA - Grant$0.00+3,61640,426+10%+$4
2018-05-31
DXCMTopol EricDirA - Grant$0.00+3,695108,257+4%+$4
2018-05-31
DXCMAugustinos NicholasDirA - Grant$0.00+3,45734,472+11%+$3
2018-05-31
DXCMAltman Steven RDirA - Grant$0.00+3,45766,312+5%+$3
2018-05-31
DXCMKahn BarbaraDirA - Grant$0.00+3,45730,905+13%+$3
2018-05-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$86.00-2,581100,658-3%-$221,963
2018-05-10
DXCMLeach Jacob StevenSVP, Research, DevelopmentG - Gift$0.00-176158,3020%-$0
2018-05-15
DXCMGregg Terrance HExec COBS - Sale$85.90-10,000524,017-2%-$858,974
D
2018-05-14
DXCMSkyler Jay SDirM - OptEx$4.58+30,00036,810+441%+$137,400
D
2018-05-14
DXCMSkyler Jay SDirS - Sale+OE$88.00-30,00036,810-45%-$2,640,000
D
2018-05-10
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.M - OptEx$7.63+2,855128,685+2%+$21,784
DM
2018-05-08
DXCMLeach Jacob StevenSVP, Research, DevelopmentM - OptEx$8.54+10,668158,478+7%+$91,151
DM
2018-05-08
DXCMLeach Jacob StevenSVP, Research, DevelopmentS - Sale+OE$84.87-13,168158,478-8%-$1,117,567
D
2018-05-09
DXCMSayer Kevin RPres, CEOM - OptEx$7.63+31,464349,390+10%+$240,070
D
2018-05-09
DXCMSayer Kevin RPres, CEOS - Sale+OE$84.37-17,245349,390-5%-$1,454,992
D
2018-05-08
DXCMSkyler Jay SDirM - OptEx$7.63+31,46436,810+589%+$240,070
D
2018-05-08
DXCMSkyler Jay SDirS - Sale+OE$85.11-31,46436,810-46%-$2,678,024
2018-04-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$73.09-2,581103,239-2%-$188,649
2018-04-16
DXCMGregg Terrance HExec COBS - Sale$73.04-10,000534,017-2%-$730,414
2018-03-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$68.44-2,581105,820-2%-$176,643
2018-03-15
DXCMGregg Terrance HExec COBS - Sale$65.51-10,000544,017-2%-$655,122
2018-03-12
DXCMMoy JeffreySVP, OperationsD - Sale to issuer$60.73-7,323138,911-5%-$444,730
2018-03-12
DXCMDoubleday RichardEVP, Chief Commercial OfficerD - Sale to issuer$60.73-9,308108,401-8%-$565,280
2018-03-12
DXCMAce Heather SSVP HRD - Sale to issuer$60.73-2,62774,232-3%-$159,539
2018-03-12
DXCMMurphy Patrick MichaelVP, Legal Aff, Chf Compl OfcrD - Sale to issuer$60.73-3,76846,180-8%-$228,833
2018-03-12
DXCMLeach Jacob StevenSVP, Research, DevelopmentD - Sale to issuer$60.73-7,453160,978-4%-$452,625
2018-03-12
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.D - Sale to issuer$60.73-9,098125,830-7%-$552,527
2018-03-12
DXCMBalo Andrew KEVP, Reg. Strategy, ClinicalD - Sale to issuer$60.73-9,519108,567-8%-$578,095
2018-03-12
DXCMAbbey DonaldEVP, Quality, Regulatory AfrsD - Sale to issuer$60.73-3,275109,953-3%-$198,893
2018-03-12
DXCMGregg Terrance HExec COBD - Sale to issuer$60.73-9,972554,017-2%-$605,606
2018-03-12
DXCMSayer Kevin RPres, CEOD - Sale to issuer$60.73-26,200335,171-7%-$1,591,142
2018-03-08
DXCMMoy JeffreySVP, OperationsA - Grant$0.00+30,093146,234+26%+$30
2018-03-08
DXCMAbbey DonaldEVP, Quality, Regulatory AfrsA - Grant$0.00+38,502113,228+52%+$39
2018-03-08
DXCMAce Heather SSVP HRA - Grant$0.00+30,09376,859+64%+$30
2018-03-08
DXCMBlackford Quentin S.EVP, CFO, PFO, PAOA - Grant$0.00+38,502102,258+60%+$39
2018-03-08
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.A - Grant$0.00+38,502134,928+40%+$39
2018-03-08
DXCMSayer Kevin RPres, CEOA - Grant$0.00+80,545361,371+29%+$81
2018-03-08
DXCMBalo Andrew KEVP, Reg. Strategy, ClinicalA - Grant$0.00+38,502118,086+48%+$39
2018-03-08
DXCMMurphy Patrick MichaelVP, Legal Aff, Chf Compl OfcrA - Grant$0.00+16,81749,948+51%+$17
2018-03-08
DXCMLeach Jacob StevenSVP, Research, DevelopmentA - Grant$0.00+30,093168,431+22%+$30
2018-03-08
DXCMGregg Terrance HExec COBA - Grant$0.00+47,087563,989+9%+$47
2018-03-08
DXCMDoubleday RichardEVP, Chief Commercial OfficerA - Grant$0.00+38,502117,709+49%+$39
2018-02-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$56.32-1,63879,021-2%-$92,252
2018-02-15
DXCMGregg Terrance HExec COBS - Sale$55.91-10,000516,902-2%-$559,095
2018-01-23
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$54.67-1,63580,659-2%-$89,384
2018-01-16
DXCMGregg Terrance HExec COBS - Sale$56.86-10,000526,902-2%-$568,588
2017-12-26
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$56.39-1,63582,294-2%-$92,204
2017-12-12
DXCMSayer Kevin RPres, CEOS - Sale$58.85-6,000280,826-2%-$353,092
2017-12-11
DXCMBalo Andrew KEVP, Reg. Strategy, ClinicalS - Sale$61.23-3,24579,547-4%-$198,691
2017-11-29
DXCMPacelli Steven RobertEVP, Strategy, Corp. Dev.S - Sale$60.12-2,90096,426-3%-$174,340
2017-11-29
DXCMBalo Andrew KEVP, Reg. Strategy, ClinicalS - Sale$60.00-6,49082,792-7%-$389,400
2017-11-27
DXCMFoletta Mark GDirS - Sale$54.95-2,50018,095-12%-$137,386
2017-11-24
DXCMDoubleday RichardEVP, Chief Commercial OfficerS - Sale$55.53-1,63583,929-2%-$90,788
AAmended filing
DDerivative transaction in filing (usually option exercise)
EError detected in filing
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
S - SaleSale of securities on an exchange or to another person
S - Sale+OESale of securities on an exchange or to another person (after option exercise)
F - TaxPayment of exercise price or tax liability using portion of securities received from the company
P - PurchasePurchase of securities on an exchange or from another person
Return to top